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Retinoids play key roles in differentiation, growth arrest, and apoptosis and are increasingly being used in the
clinic for the treatment of a variety of cancers, including neuroblastoma. Here, using a large-scale RNA inter-
ference-based genetic screen, we identify ZNF423 (also known as Ebfaz, OAZ, or Zfp423) as a component
critically required for retinoic acid (RA)-induced differentiation. ZNF423 associates with the RARa/RXRa
nuclear receptor complex and is essential for transactivation in response to retinoids. Downregulation of
ZNF423 expression by RNA interference in neuroblastoma cells results in a growth advantage and resistance
to RA-induced differentiation, whereas overexpression of ZNF423 leads to growth inhibition and enhanced
differentiation. Finally, we show that low ZNF423 expression is associated with poor disease outcome in
neuroblastoma patients.INTRODUCTION
The vitamin A metabolite retinoic acid (RA) is essential for embry-
onic and adult growth. It plays key roles in development, dif-
ferentiation, and homeostasis. These diverse effects of RA are
exerted primarily through the ability to differentially regulate
gene expression mediated by the retinoic acid receptors
(RARs). RAR belongs to the superfamily of nuclear hormone
receptors that are ligand-regulated transcription factors (Cham-
bon, 1996). RAR functions through heterodimerization with reti-
noid X receptor (RXR), which is the common partner for several
other nuclear receptors, such as vitamin D receptor (VDR),
peroxisome proliferator-activated receptor (PPAR), and thyroid328 Cancer Cell 15, 328–340, April 7, 2009 ª2009 Elsevier Inc.hormone receptor (T3R) (Mangelsdorf et al., 1995; McKenna
and O’Malley, 2002). In addition, RXR can also form homo-
dimers. As the critical dimerization component, RXR is therefore
a master regulator of many hormone responses.
RAR/RXR heterodimers constitutively associate with retinoic
acid response elements (RAREs) in promoters of target genes
(Chambon, 1996). In the absence of ligand, RAR/RXR actively
represses transcription through association with the corepres-
sors NCoR and SMRT and recruitment of histone deacetylases
(HDACs) that prevent opening of the chromatin (Chen and Evans,
1995; Horlein et al., 1995). Binding of RA to RAR induces
a conformation change of the complex. Subsequently, corepres-
sors are released and coactivator complexes are recruited toSIGNIFICANCE
Cancer biomarkers make it possible to foretell cancer outcome (prognosis) or responses to therapy (prediction). Human
neuroblastoma, the most common childhood solid tumor, has a broad range of clinical outcomes ranging from spontaneous
regression to extremely aggressive disease. We show here thatZNF423 is a prognostic biomarker for human neuroblastoma
independent of MYCN amplification. We also establish a causal role of ZNF423 in retinoic acid (RA)-induced differentiation
and proliferation of neuroblastoma cells. Thus, ZNF423 may also predict responses to RA-based therapies in the clinic.
More generally, our results underscore that the identification of components of key signaling pathways using genetic
screens can yield biomarkers with clinical utility.
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gulators requires adaptor proteins such as TBLR1 (Perissi et al.,
2004). Many of the coactivators, including CBP/p300, PCAF, and
members of the p160 family (SRC1, TIF-2/GRIP1, and ACTR/
RAC3/AIB1), possess histone acetylase (HAT) activity that
promotes transactivation of RAR/RXR (Chen et al., 1997; Onate
et al., 1995; Voegel et al., 1996). In contrast, ligand-dependent
corepressors such as RIP140, LCoR, and PRAME recruit HDACs
or polycomb group (PcG) proteins to ligand-bound RAR/RXR
complexes to repress their activities (Cavailles et al., 1995; Ep-
ping et al., 2005; Fernandes et al., 2003).
RA signaling through RAR/RXR and the subsequent activation
of target genes induce differentiation, cell-cycle arrest, and
apoptosis in many cell types. Consequently, RA displays distinct
anticarcinogenic activities, and it is currently in use or being
tested as a therapeutic agent for several human cancers (Altucci
and Gronemeyer, 2001; Freemantle et al., 2003). For example,
RA is used to treat patients suffering from acute promyelocytic
leukemia, in which translocations of RARa give rise to the
PML-RARa chimeric gene (Grignani et al., 1998; He et al.,
1998). The resulting fusion protein is a constitutive repressor
that inhibits wild-type RARa activity, thereby preventing myelo-
blast differentiation at physiological levels of RA. Pharmacolog-
ical concentrations of RA alleviate this dominant-negative block
by allowing dissociation of corepressors and recruitment of
coactivators to activate transcription. Furthermore, loss of
expression of the RA target gene RARb, an isoform of RAR, is
involved in the progression of a diverse range of solid tumors
(Altucci and Gronemeyer, 2001; Freemantle et al., 2003). As
a chemoprevention, RA treatment can be used to restore
RARb expression. For example, restoration of RARb expression
by RA therapy in premalignant oral lesions is associated with
a clinical response (Xu et al., 1995).
RA therapy has also been used in the clinic to treat human
neuroblastoma, a childhood tumor arising in the peripheral
sympathetic nervous system (Brodeur, 2003). Some tumors
regress spontaneously, but the majority of neuroblastoma
patients exhibit aggressive tumors with poor clinical outcome
despite intense therapy. While a subset of these aggressive
tumors is identified by genomic amplification of the MYCN
proto-oncogene, less is known about additional genetic factors
that control neuroblastoma tumor progression (Brodeur, 2003).
High expression of the neurotrophic receptor TRKA has been
identified as prognostic for favorable outcome, whereas TRKB
and its ligand, the brain-derived neurotrophic factor (BDNF), are
frequently expressed in unfavorable aggressive tumors with
MYCN amplification (Brodeur, 2003; Schramm et al., 2005). In
addition, the expression of FYN kinase is prognostic for good
outcome of patients independent of MYCN amplification
(Berwanger et al., 2002). Signaling through FYN kinase controls
neuroblastoma cell differentiation and proliferation. RA signaling
has also been implicated in human neuroblastoma, because high
levels of either all-trans RA or 13-cis RA induce cell proliferation
arrest and morphological differentiation of human neuroblastoma
cell lines (Reynolds et al., 1994; Sidell et al., 1983). A phase III
randomized trial demonstrated that treatment with 13-cis RA
administered after completion of intensive chemoradiotherapy
significantly improved event-free survival in high-risk neuroblas-
toma (Matthay et al., 1999). This RA therapy has now becomestandard practice to treat high-risk neuroblastoma patients after
bone marrow or stem cell transplantation.
Human ZNF423 and its mouse and rat homolog Zfp423 are
transcription factors containing 30 Kru¨ppel-like C2H2 zinc fingers
(Turner and Crossley, 1999). Zfp423 was first described as a tran-
scriptional partner of Ebf1 (Olf-1), a transcription factor impli-
cated in olfactory epithelium and lymphocyte development in
the rat (Tsai and Reed, 1997, 1998). Independently, Zfp423 was
then identified as a cofactor interacting with the Smad1/Smad4
complex in bone morphogenetic protein (BMP) signaling path-
ways (Hata et al., 2000; Ku et al., 2006). The zinc-finger clusters
of ZNF423 mediating these two signaling pathways are separable
and independent from each other. In both pathways, ZNF423
assembles a transcriptional complex by binding to distinct
partners and DNA sequences. Zfp423 is required for cerebellar
development and plays important roles in olfactory neurogenesis
and central nervous system (CNS) midline patterning in mice
(Cheng and Reed, 2007; Cheng et al., 2007; Warming et al.,
2006). Here we identify ZNF423 as a component of RA signaling
and demonstrate that it plays a key role in RA-induced differenti-
ation in several cell types, including neuroblastoma.
RESULTS
Zfp423 Is a Component of the RA Signaling Pathway
In response to RA, mouse F9 embryonic teratocarcinoma cells
differentiate into extraembryonic endoderm-like cells, recapitu-
lating early stages of mouse embryogenesis (Rochette-Egly
and Chambon, 2001). Therefore, F9 cells have been used exten-
sively as a model to investigate RA signaling in vitro. To identify
genes involved in RA signaling, we performed a large-scale RNA
interference (RNAi)-based loss-of-function genetic screen in F9
cells using a collection of 28,256 short hairpin RNA (shRNA)
vectors, which target 14,128 mouse genes (Figure 1A; see also
the Supplemental Experimental Procedures available online).
Using retroviral infection, we introduced the entire shRNA library
polyclonally into F9 cells. The infected cells were plated at low
density and exposed to 1 mM all-trans RA (henceforth referred
to as simply RA). After 4 weeks of RA selection, the resistant
colonies were pooled and total genomic DNA was isolated.
The shRNA vectors were recovered by PCR amplification and
recloned as a pool to construct a mini library. Using this function-
ally selected mini library, which was enriched for shRNA vectors
that can confer resistance to RA, we performed a second-round
selection in F9 cells. To avoid a ‘‘passenger’’ effect from irrele-
vant shRNA vectors, low multiplicity of infection was used for
infection. The resistant colonies from the second-round RA
selection were individually isolated. The shRNA inserts were
recovered by PCR, recloned, and subjected to DNA sequence
analysis to reveal their identities as described previously (Berns
et al., 2004). As an initial validation, each of the identified shRNA
vectors was individually introduced into F9 cells by retroviral
infection to retest its ability to confer resistance to RA. As a nega-
tive control, a functional shRNA targeting GFP of Aequorea
victoria was used throughout this study.
Using this approach, we identified seven different shRNA
vectors that were able to confer RA resistance in F9 cells when
expressed. We found one shRNA targeting the mouse retinoid
X receptor Rxra (shRxra) (Figure 1B), which validated the screen,Cancer Cell 15, 328–340, April 7, 2009 ª2009 Elsevier Inc. 329
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Figure 1. A Genome-wide RNAi Screen Identifies Zfp423 as a Component of the Retinoic Acid Signaling Pathway
(A) Schematic outline of the retinoic acid (RA) resistance screen performed in mouse F9 cells. A mouse shRNA library polyclonal virus was produced to infect F9
cells. The infected cells were treated with 1 mM all-trans RA (hereafter referred to as simply RA) for 4 weeks, and shRNA inserts were recovered from the resistant
colonies as described previously (Berns et al., 2004). A second-round screen was performed to enrich for shRNAs that confer RA resistance.
(B) Individual shRNAs from the library targeting Zfp423 and Rxra confer RA resistance. F9 cells expressing the control shGFP, shZfp423, or shRxra were treated
with 1 mM RA for 3 weeks, after which the cells were photographed, fixed, and stained. Scale bars = 25 mm.
(C and D) Validation of independent shRNAs targeting Zfp423 and Rxra. The functional phenotypes of nonoverlapping shRNAs targeting each gene are indicated
by the colony formation assay in 1 mM RA. The knockdown ability of each shRNA was measured by examining the mRNA levels of the intended target gene by
qRT-PCR and the protein levels by western blotting. Error bars represent SD of triplicate independent experiments.
(E) RA resistance by Zfp423 RNAi is dependent on RA signaling. Proliferation curves according to the 3T3 protocol of F9 cells expressing shRNAs targeting
Zfp423, Rxra, or GFP in the absence and presence of 1 mM RA are shown. Error bars represent SD of triplicate independent experiments.since downregulation of this receptor leads to decreased
transcriptional response to RA (see below). In addition, we also
identified one shRNA targeting Zfp423 (shZfp423) (Figure 1B).330 Cancer Cell 15, 328–340, April 7, 2009 ª2009 Elsevier Inc.To rule out that the shRNAs conferred RA resistance due to
off-target effects, we designed and tested additional nonover-
lapping shRNAs against each of the genes identified in the
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a genuine hit if at least two nonoverlapping shRNAs were able to
suppress expression of the intended target gene and confer RA
resistance (Echeverri et al., 2006). We found a direct correlation
between the knockdown abilities of the vectors and their ability
to confer resistance to RA (Figure 1C), indicating that Zfp423
was a genuine hit from the screen. Two of the most potent
shRNAs, shZfp423#1 and shZfp423#2, were used throughout
this study. We also generated multiple active shRNAs for the
geneRxra, which we considered as a positive control (Figure 1D).
Two of the most potent shRNAs, shRxra#1 and shRxra#2, were
used in subsequent experiments. For the remaining five candi-
date genes, we did not observe a correlation between knock-
down of the intended gene and the ability to confer resistance
to RA when additional shRNA vectors were tested (data not
shown), and thus these genes were not studied further.
Next, we examined whether the RA resistance mediated by
suppression of Zfp423 was due to the inhibition of RA signaling
or to a general growth advantage unrelated to RA. We performed
a long-term proliferation assay with F9 cells expressing shRNAs
against Zfp423, Rxra, or GFP in the absence or presence of
exogenous RA using the 3T3 protocol (Figure 1E). In the absence
A
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Figure 2. Zfp423 Is Also Required for RA-Induced Differentiation
in Mouse Embryonic Stem Cells
(A) Downregulation of Zfp423 by RNAi in E14T mouse embryonic stem (ES)
cells confers resistance to RA-induced differentiation. E14T cells expressing
shRNAs against GFP (control), Zfp423, or Rxra were grown in the absence
or presence of 1 mM RA for 1 week, after which cells were fixed, stained for
alkaline phosphatase (AP), and photographed. Scale bars = 50 mm.
(B) mRNA levels of Zfp423 and Rxra in E14T mouse ES cells expressing
shRNAs targeting GFP, Zfp423, or Rxra. Error bars represent SD of triplicate
measurements.of RA, no significant growth difference was detected in any cell
lines. When exposed to 1 mM RA, the cells expressing shRNAs
targeting Zfp423 or Rxra continued to proliferate, while the
control cells were drastically inhibited. These data argue against
a generalized growth advantage for the Zfp423 knockdown F9
cells and suggest a specific resistance to RA-induced growth
arrest.
Zfp423 Is Also Required for RA-Induced Differentiation
in Mouse Embryonic Stem Cells
In addition to F9 cells, mouse embryonic stem (ES) cells have
been used as another cellular system to study RA-induced differ-
entiation in vitro (Rohwedel et al., 1999). We observed that
mouse ES cells also express a high level of Zfp423 (data not
shown). Therefore, we examined the role of Zfp423 in RA-
induced differentiation in this cellular system. shRNAs against
Zfp423, Rxra, or GFP were introduced into E14T mouse ES cells
by retroviral infection. As expected, the knockdown abilities of
these shRNAs in E14T cells were comparable to those seen in
F9 cells (Figure 2B; Figures 1C and 1D). The infected cells
were plated at low density and cultured in the absence or pres-
ence of 1 mM RA for 1 week. The surviving cells were then stained
for alkaline phosphatase (AP), a marker of undifferentiated ES
cells. In the absence of RA, there was no significant difference
in cell growth and maintenance of the undifferentiated state in
any knockdown lines (Figure 2A). In the presence of RA, prolifer-
ation of the control cells was severely inhibited and the remaining
differentiated cells failed to stain for AP (Figure 2A). In contrast,
cells stably expressing shRNAs against Zfp423 or Rxra
continued to proliferate and stained positively for AP
(Figure 2A). Hence, Zfp423 appears to be also required for
RA-induced differentiation in mouse ES cells.
ZNF423 Is a Transcriptional Cofactor of Retinoic
Acid Receptors
Zfp423 was first implicated as a transcriptional partner of Ebf1 in
olfactory epithelium and lymphocyte development in the rat and
was then identified as a transcriptional activator and Smad1/
Smad4 cofactor in regulating BMP signaling. Therefore, we
tested whether ZNF423 can also act as a cofactor for RARa/
RXRa transactivation. ShRNAs targeting Zfp423, Rxra, or GFP
were cotransfected with a reporter gene containing consensus
RAREs linked to luciferase (RARE-Luc) into F9 cells (Epping
et al., 2005). Both shRNAs against Zfp423 inhibited the reporter
gene activation by RA, similar to the shRNAs targeting Rxra
(Figure 3A), indicating that Zfp423 is required for transcriptional
activation of Rara/Rxra in response to RA. As an independent
cellular system, we performed the RARE-Luc reporter assays
in NTERA2 human embryonic teratocarcinoma cells, which
also express a high level of ZNF423 (Figure S1). Similarly,
shRNAs targeting human ZNF423 and RXRa (see below) also
suppressed RA-induced expression of the reporter gene
(Figure 3B). Conversely, expression of both wild-type ZNF423
and FLAG-ZNF423DN (which lacks the first 60 amino acids but
contains all 30 zinc fingers) was able to hyperactivate the
RARE-Luc reporter in response to RA (Figure 3C). The difference
in the ability of ZNF423 and FLAG-ZNF423DN to activate
reporter expression probably reflects the fact that FLAG-
ZNF423DN was more highly expressed than wild-type ZNF423Cancer Cell 15, 328–340, April 7, 2009 ª2009 Elsevier Inc. 331
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a cofactor for RARa/RXRa transactivation.
Using a similar approach, we found that ZNF423 is required for
activation of the RARE-Luc reporter induced by RAR-selective
agonists for all isoforms: RARa, b, and g (Figure S2). Consistent
with these results, coexpression of ZNF423 sensitized the RA
response in Rara,b,g triple-knockout (TKO) mouse embryonic
fibroblasts (MEFs) reconstituted with each of the three RAR
isoforms (Figure S3) (Epping et al., 2007). Furthermore,
ZNF423 was also required for both reporter gene activation
and growth inhibition induced by an RXR-selective ligand in
mouse F9 and human SH-SY5Y neuroblastoma cells (Figures
S4 and S5). Together, these results indicate that ZNF423 is a
critical cofactor for all three retinoic acid receptors.
To further substantiate that Zfp423 knockdown inhibits
RA-induced transcription, we analyzed mRNA expression levels
of a panel of eight bona fide RA target genes, including Rarb and
Crabp2, in F9 cells. As expected, all eight target genes were
drastically induced in control cells following exposure to RA
(Figures 3D and 3E; Figure S6). However, induction of these
genes was significantly inhibited in cells expressing shZfp423
A D
B E
C F
Figure 3. ZNF423 Is a Transcriptional
Cofactor for RXRa/RARa
(A–C) Activation of a retinoic acid response
element-luciferase (RARE-Luc) reporter gene by
RXRa/RARa requires ZNF423. Normalized lucif-
erase activities shown represent ratios between
luciferase values andRenilla internal control values
and are the average ± SD from three independent
transfections.
(A) Downregulation of Zfp423 by RNAi inhibits
transcriptional induction of the RARE-Luc reporter
gene in mouse F9 cells in response to 24 hr of 1 mM
RA stimulation.
(B) Suppression of ZNF423 by RNAi inhibits the
activation of the RARE-Luc reporter gene in human
NTERA2 cells in response to 1 mM RA treatment.
(C) Overexpression of both wild-type ZNF423 and
the epitope-tagged mutant FLAG-ZNF423DN
(which lacks the first 60 amino acids but contains
all 30 zinc fingers) was able to hyperactivate the
luciferase expression induced by 1 mM RA.
(D–F) Zfp423 is required for transcriptional regula-
tion of endogenous RA target genes in response to
RA. mRNA expression analysis of the RA target
genes Rarb (D), Crabp2 (E), and Wnt6 (F) in F9 cells
expressing shRNAs targetingGFP,Zfp423, orRxra
after 1 mM RA stimulation for 48 hr is shown.
Error bars represent SD of triplicate independent
experiments.
or shRxra (Figures 3D and 3E;
Figure S6). In addition, it has been shown
that Wnt6 expression is downregulated in
F9 cells upon RA treatment (Eifert et al.,
2006). We also observed this repression
of Wnt6 in control F9 cells in response to
RA, but not in cells stably expressing
shZfp423 or shRxra (Figure 3F). These
results further demonstrate that ZNF423
is required for RXRa/RARa transcriptional regulation in response
to RA.
In contrast, Zfp423 appeared not to be required for Rara-
mediated transcriptional repression in the absence of RA in F9
cells (Figure S6). Consistent with this, ZNF423 was not required
for transcriptional repression of GAL4-luciferase by GAL4-RARa
in the absence of RA (Figure S7).
Interaction of ZNF423 with Retinoic Acid Receptors
In Vitro and In Vivo
To investigate the possible physical interaction between ZNF423
and RARa/RXRa, we performed GST pull-down experiments
using recombinant GST fusions of RXRa, RARa, and in vitro-
translated ZNF423. ZNF423 associated with GST-RXRa and
GST-RARa in both the absence and presence of RA
(Figure 4A). As a control for proper folding of the fusion proteins,
heterodimerization between GST-RXRa and RARa or vice versa
was observed, but homodimerization of RARa or RXRa was
inefficient under the conditions used (Figure 4A). To determine
whether ZNF423 binds RARa/RXRa in vivo, we performed coim-
munoprecipitation experiments in parental F9 cells. Endogenous332 Cancer Cell 15, 328–340, April 7, 2009 ª2009 Elsevier Inc.
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(Figure 4B), indicating that Zfp423 and Rara/Rxra form a stable
complex under physiological conditions in vivo. Consistent
with the in vitro binding results, the association of Zfp423 with
Rara/Rxra in F9 cells did not require RA but was slightly
enhanced when cells were treated with 1 mM RA. This enhanced
interaction in response to RA coincided with the slight increase in
Zfp423 protein and mRNA levels after RA exposure (Figure 4B
and data not shown).
Since ZNF423 directly associates with RXRa and is required
for transactivation of all three RARs, we predicted that ZNF423
would also interact with RARb and RARg in addition to RARa.
Indeed, all RAR isoforms were able to coimmunoprecipitate
with ZNF423 in cells transfected with pSG5-RXRa/RARa either
with or without pCS2-FLAG-ZNF423DN (Figure S8).
Zfp423 Interacts with the RARE Region
of the Rarb Promoter
Since Zfp423 forms a stable complex with Rara/Rxra and is
required for their transcriptional regulation in response to RA,
we examined whether Zfp423 interacts with the promoters of
bona fide RA target genes in chromatin. Using antibodies for
Zfp423, Rxra, or control IgG and primers sets flanking the
RARE region of the Rarb promoter, we performed chromatin
immunoprecipitation (ChIP) assays on F9 cells followed by quan-
A
C
B Figure 4. ZNF423 Physically Associates with RARa/
RXRa and the RARE Region of the Rarb Promoter
(A) In vitro binding of ZNF423 to RXRa and RARa. GST pull-
down assay showing the interactions of in vitro-translated
35S-labeled ZNF423 with recombinant GST-RXRa and GST-
RARa independent of 1 mM RA is shown. The same protein
preparations were used to demonstrate heterodimerization
between GST-RXRa and in vitro-translated RARa and
between GST-RARa and in vitro-translated RXRa.
(B) In vivo interaction of Zfp423 and the Rara/Rxra complex in
mouse F9 cells. Rxra and Rara were immunoprecipitated (IP)
using their specific antibodies (labeled as aRxra and aRara;
IgG was used as a control) in the absence or presence of
1 mM RA. The precipitates were immunoblotted for Zfp423,
Rxra, Rara, and g-tubulin.
(C) Zfp423 is associated with the RARE region of the Rarb
promoter. Chromatin immunoprecipitation analysis demon-
strates the promoter occupancy by endogenous Zfp423 on
the Rarb promoter in parental F9 cells. Quantitative PCR was
used to show promoter occupancy using two primer sets in
the proximity of the RARE and one control primer set located
1.5 kb distal to the RARE region. Specific enrichment of Rarb
promoter occupancy was observed in the Zfp423 and Rxra
immunoprecipitates as compared to IgG control immunopre-
cipitate in both the absence and the presence of 1 mM RA.
Error bars represent SD of triplicate measurements.
titative PCR (qPCR). Rxra, used as a positive
control, showed strong and specific interaction
with the RARE region (Figure 4C). Zfp423 was
also significantly associated with theRarb promoter
in direct proximity to the RARE in both the presence
and the absence of RA, while its occupancy in the
region distal to the RARE was minimal (Figure 4C).
The small increase in Zfp423 occupancy in the RARE region after
RA treatment is consistent with the increased association
between Zfp423 and Rara/Rxra and may be a consequence of
the upregulation of Zfp423 levels as described above (Figure 4B).
ZNF423 Is Critical for Cell Growth and Differentiation
of Neuroblastoma
RA is a neural differentiation agent, and RA signaling has been
implicated in differentiation of human neuroblastoma cells (Rey-
nolds et al., 1994; Sidell et al., 1983). Clinical trials have shown
that RA treatment after completion of intensive chemoradiother-
apy significantly improves survival in high-risk neuroblastoma
patients (Matthay et al., 1999; Reynolds et al., 2003). Our finding
that ZNF423 is a critical cofactor for RXRa/RARa and the notion
that Zfp423 is involved in neural development in mice (Cheng
and Reed, 2007; Cheng et al., 2007; Warming et al., 2006) sug-
gested a possible role for ZNF423 in human neuroblastoma.
Furthermore, ZNF423 is expressed in many neuroblastoma cell
lines (Figures S11 and S12). Therefore, we investigated whether
ZNF423 is causally involved in cell growth and differentiation of
human neuroblastoma cell lines. In response to RA treatment,
many neuroblastoma cell lines exhibited arrest of proliferation
and/or morphological differentiation (Figure 5; Figure S9; data
not shown). Similar to the RA-induced upregulation of Zfp423
in F9 cells, we also observed a small increase of ZNF423Cancer Cell 15, 328–340, April 7, 2009 ª2009 Elsevier Inc. 333
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RA treatment (Figure 5C). Downregulation of ZNF423 expression
by multiple nonoverlapping shRNA vectors conferred resistance
to the potent effects induced by RA in SH-SY5Y, SK-N-SH, and
SK-N-FI neuroblastoma cells, which are non-MYCN-amplified
(Figure 5 and data not shown). Similar results were also obtained
inMYCN-amplified cells such as SK-N-BE, IMR32, and SK-N-AS
cells (Figure S9 and data not shown), indicating that the role of
ZNF423 in RA signaling in neuroblastoma cells is independent
of MYCN status. Consistent with the RA resistance caused by
ZNF423 knockdown, the induction of the RA target genes
RARb and CRABP2 was significantly inhibited in SH-SY5Y cells
stably expressing shRNAs against ZNF423 or RXRa (Figure 6).
To address whether ZNF423 knockdown interferes with
neuroblastoma differentiation, we also examined the expression
A
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Figure 5. Suppression of ZNF423 Leads to a
Growth Advantage and Resistance to RA-
Induced Differentiation in Neuroblastoma
(A) Downregulation of ZNF423 or RXRa in
SH-SY5Y cells by RNAi results in a growth advan-
tage in the absence of exogenous RA and
resistance to RA-induced growth inhibition and
differentiation. SH-SY5Y cells expressing shRNAs
against controlGFP, ZNF423, orRXRawere grown
in the absence or presence of 0.1 mM exogenous
RA, after which cells were fixed, stained, and pho-
tographed. Cells were harvested after 20 days
(untreated) or 35 days (RA treatment).
(B) Proliferation curves according to the 3T3
protocol of SH-SY5Y cells expressing shRNAs tar-
geting ZNF423, RXRa, or GFP in the absence (left)
or presence (right) of 0.1 mM exogenous RA. Error
bars represent SD of triplicate measurements.
(C) ZNF423 mRNA and protein levels were slightly
induced in SH-SY5Y cells in response to 2 weeks
of 0.1 mM RA treatment, and suppression of
ZNF423 by shRNAs blocked this induction as
well as the basal expression in the absence of RA.
Error bars represent SD of triplicate measure-
ments.
(D) Downregulation of RXRa mRNA levels by
shRNAs targeting RXRa in SH-SY5Y cells (±0.1 mM
RA). Error bars represent SD of triplicate measure-
ments.
of several critical neural differentiation
markers, the neurotrophic receptors
TRKA and TRKB as well as the receptor
for glial cell-derived neurotrophic factor
(GDNF), RET. It has been shown that
expression of these receptor kinases is
induced upon RA treatment and that
these receptors are causally involved in
RA-induced differentiation in neuroblas-
toma cells in culture (Esposito et al.,
2008; Kaplan et al., 1993; Peterson and
Bogenmann, 2004). When control SH-
SY5Y cells were exposed to RA for
2 weeks, mRNA levels of TRKA, TRKB,
and RET were induced (Figure 6). In
contrast, the induction of these neurotro-
phic receptors in cells expressing shRNAs against ZNF423 or
RXRa was significantly inhibited (Figure 6).
Conversely, enforced expression of ZNF423 in SH-SY5Y and
SK-N-SH cells led to hypersensitivity to RA, as evidenced by
growth inhibition (Figures S10A and S10B and data not shown).
As expected, SH-SY5Y cells expressing exogenous ZNF423
induced higher levels of RA target genes and neural differentia-
tion markers in response to RA treatment (Figure S10C). More-
over, expression of ZNF423 in RA-insensitive SHEP cells that
have undetectable levels of ZNF423 restored the defective RA
response (Figure 7; Figure S11). Collectively, these results
demonstrate that ZNF423 is required for RA-induced differentia-
tion in neuroblastoma cells.
Surprisingly, we also noticed a growth advantage in neuroblas-
toma cells expressing shRNAs against ZNF423 or RXRa in the334 Cancer Cell 15, 328–340, April 7, 2009 ª2009 Elsevier Inc.
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taining 8% FCS) (Figure 5 and data not shown). This growth
advantage was also observed, but to a lesser extent, in IMR32
and SK-N-AS cells with MYCN amplification (data not shown).
Conversely, ectopic expression of ZNF423 in SHEP, SH-SY5Y,
or SK-N-SH cells resulted in growth inhibition even when cultured
in the absence of exogenous RA (Figure 7; Figure S10; data not
shown). These effects of ZNF423 knockdown and overexpres-
sion could be partially due to low concentrations of RA present
in the serum-containing culture medium (see also Discussion).
Expression of ZNF423 Is Prognostic for Survival
of Neuroblastoma Patients
Given the role of ZNF423 in neuroblastoma growth and differen-
tiation, we investigated a possible correlation between ZNF423
expression and progression-free survival in human neuroblas-
toma patients. The initial analysis was performed using a cohort
of 88 human neuroblastoma patients (72 without MYCN amplifi-
cation and 16 with MYCN amplification; see also Tables S2
and S3) from the Academic Medical Center (AMC) in Amsterdam.
The expression data were obtained by microarray analysis
(Affymetrix platform) of the primary tumor samples of these
Figure 6. ZNF423 Is Required for Transcriptional
Responses of RA Target Genes and Neural Differenti-
ation Markers in Neuroblastoma
Suppression of ZNF423 and RXRa in SH-SY5Y cells by RNAi
leads to reduced expression of RA target genes and neural
differentiation markers in both the absence and the presence
of exogenous RA (see also Figure S4). mRNA levels of RARb,
CRABP2, TRKA, TRKB, and RET in SH-SY5Y cells expressing
shRNAs targeting GFP, ZNF423, or RXRa were analyzed by
qRT-PCR after the cells had grown in the absence or presence
of 0.1 mM exogenous RA for 14 days. Error bars represent SD
of triplicate measurements.
patients at the time of diagnosis, prior to any treat-
ment. Using this cohort as a ‘‘training set,’’ a cutoff
value of ZNF423 expression was determined using
leave-one-out cross-validation (see also Experi-
mental Procedures and Table S3). The patients
were then classified into two groups based on
ZNF423 expression in their primary tumors using
this cutoff value, and Kaplan-Meier analysis for
progression-free survival was performed. Interest-
ingly, a high level of ZNF423 expression was asso-
ciated with good outcome of patients (all stages
combined), and low ZNF423 expression was
associated with poor outcome (Figure 8A, left;
p = 2.9e-03). This potential prognostic value of
ZNF423 expression was also significant in the
subset of 72 patients with tumors lacking MYCN
amplification (Figure 8A, right; p = 4.5e-03) but
appeared not to be statistically significant in the
16 patients with tumors having MYCN amplification
(p = 0.494; data not shown), likely due to the small
number of patients in this subgroup.
Next, we validated the prognostic value of
ZNF423 using a second independent cohort of 102
patients with metastatic neuroblastoma tumors lacking MYCN
amplification (Asgharzadeh et al., 2006). Since the gene expres-
sion data of the second cohort were also based on the same
microarray platform, the ZNF423 expression values from both
data sets were normalized, and the same ZNF423 cutoff value
determined in the AMC cohort was used for the validation study
(see Supplemental Experimental Procedures). Similar results
were obtained in the second cohort: a high level of ZNF423
expression was associated with good outcome of patients in
progression-free survival, and low ZNF423 expression was
associated with poor outcome (Figure 8C; p = 3.3e-04). Thus,
these results validate the prognostic value of ZNF423 in
neuroblastoma. Furthermore, using this validated ZNF423 cutoff
value, multivariate analysis of the AMC cohort with other clinically
relevant parameters showed that expression of ZNF423
predicted survival independently of MYCN amplification and
patient age (Figure 8B).
This prognostic value of ZNF423 is further supported by a third
independent data set of 101 neuroblastoma patients (81 without
MYCN amplification and 20 with MYCN amplification) (Wang
et al., 2006), where ZNF423 expression was high in tumors of
early-stage disease but lower in more advanced-stage diseaseCancer Cell 15, 328–340, April 7, 2009 ª2009 Elsevier Inc. 335
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observed in the subset of 81 patients with tumors lacking
MYCN amplification (Figure 8D, right; p = 3.1e-03). Since
MYCN-amplified tumors existed only in stage 4 of this cohort,
such correlation analysis of ZNF423 expression and stages
could not be performed in this subgroup.
When we expressed ZNF423 in human neuroblastoma cells
and performed global gene expression analysis, we found that
852 genes were >2-fold regulated by ZNF423 (NCBI GEO acces-
sion number GSE14627). Of these 852 genes, 142 (see Table S4)
were also significantly differentially expressed in the ‘‘ZNF423
high’’ versus the ‘‘ZNF423 low’’ cohort of 102 neuroblastomas
(Asgharzadeh et al., 2006). Randomization analyses demon-
strate that the genes that respond to ZNF423 expression
in vitro are also statistically significantly associated with
ZNF423 expression in patient tumors (Figure S13).
In summary, these multiple expression analyses in patient
tumors indicate that expression of ZNF423 is prognostic for
outcome in human neuroblastoma patients.
DISCUSSION
We identified ZNF423 in an unbiased genome-wide RNAi screen
for additional components of the RA signaling pathway and
found that it is a critical cofactor of RA-induced transcription
that interacts with RARa/RXRa. Subsequently, we demonstrated
that ZNF423 is critical for growth and differentiation of neuro-
blastoma cells and identified the prognostic value of ZNF423
expression in long-term survival of human neuroblastoma
patients.
Previous studies have indicated that ZNF423 is a multifunc-
tional transcriptional regulator that uses distinct sets of its zinc
fingers to regulate different signaling pathways. In this study,
we provide several lines of evidence for a function of ZNF423
A
C
B Figure 7. Enforced Re-expression of ZNF423Restores
RA Sensitivity in Neuroblastoma
(A) Re-expression of ZNF423 in SHEP cells that have undetect-
able levels of ZNF423 (see also Figure S11) leads to growth
inhibition in the absence of exogenous RA and enhanced
responses to RA. Cells retrovirally infected with MSCV control
or MSCV-ZNF423 were grown in the absence or the presence
of 0.1 mM exogenous RA for 9 days, after which cells were
fixed, stained, and photographed.
(B) Relative ZNF423 mRNA levels in SHEP cells retrovirally
infected with MSCV control or MSCV-ZNF423 (±0.1 mM RA).
Error bars represent SD of triplicate measurements.
(C) Graphical view of SHEP cell growth (±0.1 mM RA) based on
crystal violet staining. Compared to control cells, cells infected
with MSCV-ZNF423 showed growth suppression and
enhanced RA sensitivity. Error bars represent SD of triplicate
measurements.
in positively regulating cellular responses to RA.
First, suppression of ZNF423 expression by RNAi
conferred resistance to RA-induced differentiation
in mouse teratocarcinoma cells, mouse ES cells,
and a panel of human neuroblastoma cells.
Conversely, ectopic expression of ZNF423 in
RA-insensitive neuroblastoma cells with undetect-
able levels of ZNF423 restored the RA response. Second,
suppression of ZNF423 by RNAi in mouse teratocarcinoma
and human neuroblastoma cells impaired the full induction of
endogenous RA target genes in response to RA treatment, indi-
cating that ZNF423 is a critical cofactor required for RARa/RXRa
transactivation. Third, ZNF423 interacts with RARa/RXRa both
in vitro and in vivo, and ZNF423 associates with RAREs of the
promoter region of RA target genes in ChIP experiments.
The interaction between ZNF423 and RARa/RXRa does not
require RA either in vitro or in vivo, and consistent with this, we
found that Zfp423 constitutively associated with the RARE of
the Rarb promoter. However, ZNF423 does not appear to be
required for repression by the unliganded RAR (Figure S7). More-
over, in line with previous observations (Hata et al., 2000), we did
not detect any intrinsic ability of ZNF423 to activate transcription
(data not shown). Taking these findings together, we propose
a role for ZNF423 as a transcriptional intermediary factor for
RARa/RXRa: it constitutively associates with the promoters of
RA target genes and may prime the RA receptors to recruit other
essential factors required for RARa/RXRa transactivation in
response to RA. Identification of these critical factors recruited
by ZNF423 will yield further insights into the regulation of
RARa/RXRa transactivation.
Previous studies have indicated that Zfp423 plays an impor-
tant role in neural development in mice: deletion of Zfp423
results in severe cerebellar defects and impaired olfactory neu-
rogenesis as well as CNS midline patterning in mice (Cheng
and Reed, 2007; Cheng et al., 2007; Warming et al., 2006). These
effects of Zfp423 appear to coincide with a central role of RA
signaling in neuronal differentiation and CNS patterning in
animals (Maden, 2002; McCaffery et al., 2003). Rar knockout
mice exhibit neural crest defects and disorganized hindbrain,
and these effects can be mimicked by the use of a pan-RAR
antagonist. These in vivo phenotypes are consistent with the336 Cancer Cell 15, 328–340, April 7, 2009 ª2009 Elsevier Inc.
Cancer Cell
ZNF423 Is Required for RA-Induced DifferentiationA
B
C D
Figure 8. Expression of ZNF423 Is Prognostic for Survival of Human Neuroblastoma Patients
(A) Kaplan-Meier analysis of the Academic Medical Center (AMC) cohort documenting increased progression-free survival of neuroblastoma patients with tumors
that have high ZNF423 expression (ZNF423 high) versus patients with tumors that have low ZNF423 expression (ZNF423 low), using the ZNF423 cutoff value
determined as described in the text. The analysis in the left diagram was performed in 88 tumors including all stages (stage 1 to 4S); the right diagram presents
a subanalysis of 72 tumors lacking MYCN amplification.
(B) Multivariate analysis of the AMC cohort using ZNF423 expression and other clinically relevant parameters including MYCN amplification, loss of heterozy-
gosity of chromosome 1p (LOH 1p), age, and stage (see also Experimental Procedures). Expression of ZNF423 predicted survival independently of MYCN
amplification and patient age. CI denotes confidence intervals; statistically significant parameters are shown in bold. All patients (n = 88) were included in the
entire analysis except for the studies with LOH 1p (n = 82) due to the undetermined LOH 1p status in 6 patients.
(C) Kaplan-Meier analysis of progression-free survival for a second independent set of 102 patients diagnosed with metastatic neuroblastomas lacking MYCN
amplification (Asgharzadeh et al., 2006). These patients were classified using the same ZNF423 cutoff value determined from the AMC cohort.
(D) Decreased expression of ZNF423 correlates with advanced tumor stages in a third independent set of 101 neuroblastoma patients (Wang et al., 2006). The
analysis in the left diagram was performed in all of the patients (81 without MYCN amplification and 20 with MYCN amplification); the right diagram presents
a subanalysis of the 81 tumors lacking MYCN amplification. ST1, stage 1 (n = 28*); ST3, stage 3 (n = 23); ST4, stage 4 (n = 53). *One stage 2 patient was included
in the stage 1 group due to the low patient number in the stage 2 group (n = 1).Cancer Cell 15, 328–340, April 7, 2009 ª2009 Elsevier Inc. 337
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here.
In the absence of exogenous RA, we also observed effects on
cell proliferation and differentiation by ZNF423 knockdown and
overexpression in many of the neuroblastoma cell lines. It is
possible that the endogenous amount of RA in the regular 8%
FCS growth medium is sufficient to activate RA signaling at
a low level in these human neuroblastoma cells. Alternatively,
other pathways such as the BMP and OLF/EBF pathways, in
which ZNF423 is also causally involved, could be important for
neuroblastoma genesis. BMP2 treatment results in growth arrest
and differentiation in human neuroblastoma cell lines, and OLF/
EBF transcription factors have also been implicated in neuro-
blastoma differentiation (Nakamura et al., 2003; Persson et al.,
2004). In fact, a synergistic effect of RA and BMP6 on differenti-
ation of human neuroblastoma cells has been demonstrated in
culture (Sumantran et al., 2003). As the common mediator for
both the RA and BMP pathways, ZNF423 might be the critical
factor contributing to this synergy. We therefore cannot rule
out the possibility that other RA-independent pathways are
also responsible for the prognostic value of ZNF423 expression.
Since RA induces growth arrest, differentiation, and
apoptosis, one might speculate that ZNF423, being an essential
mediator of the RA response, has tumor suppressor-like proper-
ties in neuroblastoma. However, we did not observe loss of
heterozygosity at chromosome 16q12, the ZNF423 locus, in
a panel of 88 human neuroblastomas, nor did we find that human
neuroblastoma cell lines that do not express ZNF423 could be
made to re-express the gene after treatment with DNA demethy-
lating agents (data not shown).
RA-based therapies are also used in leukemias, most notably
in acute promyelocytic leukemia (APL). However, we did not
observe any ZNF423 expression in two leukemia cell lines,
including one APL (Figure S11). This is in agreement with the
neural-restricted expression pattern of ZNF423 (http://
symatlas.gnf.org/SymAtlas/) and the neural-specific phenotype
of Zpf423 knockout mice (Cheng and Reed, 2007; Cheng
et al., 2007; Warming et al., 2006). Thus, ZNF423 may not be
a regulator of the RA response in leukemia. However, since the
ZNF gene family consists of some 700 members, it is possible
that another ZNF family member is required for RA responses
in other cell types.
Remarkably, in three independent gene expression data sets
of over 300 neuroblastomas, we found that low expression of
ZNF423 predicted poor outcome. Multivariate analysis shows
that ZNF423 prognostic value is independent of MYCN status
(Figure 8). These findings are significant since MYCN amplifica-
tion only accounts for a subset of aggressive neuroblastoma
tumors, while the remainder lack consistently identifiable
biomarkers. ZNF423 expression could therefore serve as a prog-
nostic biomarker for neuroblastoma tumors independent of
MYCN amplification.
In summary, our data indicate that low ZNF423 expression is
associated with poor outcome in neuroblastoma and clearly
implicate ZNF423 in RA signaling. Expression levels of ZNF423
could significantly affect responses to both endogenous and
pharmacological concentrations of RA in cancer patients, which
may in turn influence the outcome of neuroblastoma. Therefore,
ZNF423 may also be a biomarker predicting responses to338 Cancer Cell 15, 328–340, April 7, 2009 ª2009 Elsevier Inc.RA-based therapies, which are increasingly being used to treat
neuroblastoma. Additional clinical studies will be needed to
validate this potential predictive power of ZNF423 expression
for retinoid-based therapies in human neuroblastoma.
EXPERIMENTAL PROCEDURES
shRNA Library
The NKI mouse shRNA library (containing 28,256 shRNA vectors that target
14,128 mouse genes) was constructed into the pRISC retroviral vector, which
is derived from pRETRO-SUPER with an additional chloramphenicol resis-
tance marker under regulation of the TET promoter (Brummelkamp et al.,
2002). The details of this library can be found in the Supplement Data and
can also be viewed at http://www.screeninc.nl/.
Transfections and Reporter Assays
Transfections were carried out using calcium phosphate precipitation. RARE-
Luc reporter assays were performed in DMEM supplemented with charcoal-
stripped FCS (HyClone) essentially as described previously (Epping et al.,
2007).
GST Pull-down Assays, Western Blotting, Coimmunoprecipitation,
and Chromatin Immunoprecipitation
These experiments were performed according protocols described previously
(Epping et al., 2005). Normal rabbit IgG, anti-RXRa (D-20), and anti-ZNF423
(H-105) were used for ChIP. The sequences of the primer sets used for
ChIP-qPCR analysis are listed in Table S1.
Patient Samples
For all three independent studies presented, the expression data were
obtained using Affymetrix microarray analyses on untreated primary tumor
samples at the time of diagnosis. For the cohort of 88 neuroblastoma patients
from the AMC (Amsterdam), material was obtained during surgery and
immediately frozen in liquid nitrogen. MYCN amplifications and loss of hetero-
zygosity of chromosome 1p (LOH 1p) were determined using Southern blot
analysis of tumor material and lymphocytes from the same patient. Patient
samples for the other two cohorts were as described previously (Asgharzadeh
et al., 2006; Wang et al., 2006). Written informed consent was obtained from
patients’ parents or guardians in accordance with Institutional Review Board
policies and procedures for research dealing with tumor specimens and
clinical information. The Institutional Review Board at Childrens Hospital Los
Angeles and the Medical Ethics Committee of the AMC approved the study.
Statistical Analysis
To determine the optimal value to set as a cutoff for ZNF423 expression in the
AMC cohort, leave-one-out cross-validation was used. The neuroblastoma
patients were sorted based on expression of ZNF423 and subsequently
divided into two groups based on the expression value of each patient. For
each group separation (higher or lower than the current ZNF423 expression),
the log-rank significance was calculated. The best p value out of the sequence
was then used to represent the final gene expression cutoff value for ZNF423.
This cutoff value was validated using a second independent set of 102 patients
(Asgharzadeh et al., 2006) (Supplemental Experimental Procedures).
Progression-free survival was measured for all outcome analyses presented
in this study using the same ZNF423 cutoff value. The definition of an event for
the AMC cohort (all stages) was progressive disease, recurrent disease, or
death of the patient. For the second cohort with metastatic neuroblastomas
lacking MYCN amplification, disease progression was defined as develop-
ment of any new lesion, >25% increase of any measurable tumor mass, or
previously negative bone marrow becoming positive for tumor cells.
For multivariate analysis, Cox regression calculations on progression-free
survival were performed using SPSS version 15.0. For these calculations,
single covariates (ZNF423, MYCN, LOH 1p, stage, age) as well as double
covariates in a nonsequential model (MYCN, LOH 1p, stage, age) in combina-
tion with the ZNF423 cutoff were used. The variable ‘‘stage’’ consisted of two
groups based on the International Neuroblastoma Staging System: (1) ST1, 2,
3, and 4S and (2) ST4. The variable ‘‘age’’ (of diagnosis) consisted of two
Cancer Cell
ZNF423 Is Required for RA-Induced Differentiationgroups: (1)%18 months and (2) >18 months. Hazard ratios, p values, and 95%
confidence intervals were part of the SPSS output.
ACCESSION NUMBERS
The gene expression data for SH-SY5Y cells with and without overexpression
of ZNF423 are available at the NCBI Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo/) under the accession number GSE14627.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, thirteen figures, and four tables and can be found
with this article online at http://www.cancercell.org/supplemental/
S1535-6108(09)00075-0.
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